Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Eli Lilly (LLY) ACCELERATE Trial Proves 'Modestly Positive' for Esperion Therapeutics (ESPR) LDL Hypothesis - Stifel
October 12, 2015 3:07 PM EDTStifel analyst Thomas Shrader weighed in on Esperion Therapeutics (NASDAQ: ESPR) following what he called "confusion in the world of LDL lowering drugs" after the ACCELERATE trial for the CETP inhibitor evacetrapib has been stopped for futility by its sponsor Eli Lilly (NYSE: LLY). Shrader said what seems less understood is that "based on this trials inclusion and exclusion criteria, this trial involved patients with controlled... More
Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)
October 12, 2015 9:13 AM EDTNews Eli Lilly (NYSE: LLY) plans to halt development of evacetrapib, a CETP inhibitor, has positive implications for PCSK-9 -related stocks and Esperion Therapeutics (NASDAQ: ESPR), said RBC analyst Michael J. Yee.
Yee explained, "The CETP class of drugs has been the primary competitive threat to other drugs like AMGN (Nasdaq: AMGN), REGN's (Nasdaq: REGN) PCSK-9 drugs now approved and ESPR's Phase III oral drug ETC-1002. Recall there is also one... More
UPDATE: Esperion (ESPR), Others Gains After Lilly Halts Development of Evacetrapib; Merch (MRK) Falls
October 12, 2015 8:15 AM EDT(Updated - October 12, 2015 8:30 AM EDT)
Esperion Therapeutics (NASDAQ: ESPR) gained pre-market Monday after Eli Lilly & Co. (NYSE: LLY) discontinued development of Evacetrapib. Other gainers include makers of PCSK9 cholesterol drugs Regeneron (NASDAQ:... More
